Tech Company Financing Transactions
Encoded Therapeutics Funding Round
Encoded Therapeutics, based in San Francisco, raised $104 million from Alexandria Venture Investments, Altitude Life Science Ventures and Arch Venture Partners.
Transaction Overview
Company Name
Announced On
6/27/2019
Transaction Type
Venture Equity
Amount
$104,000,000
Round
Series C
Investors
Proceeds Purpose
Encoded will use the funds to advance its lead program in Dravet Syndrome and its preclinical pipeline, as well as to leverage its platform to develop new therapeutics to treat severe genetic disorders.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
341 Oyster Point Blvd.
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Encoded Therapeutics, Inc., is a biotechnology company developing precision gene therapies for a broad range of severe genetic disorders. Our mission is to realize the potential of genomics-driven precision medicine by overcoming key limitations of viral gene therapy.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Sean Nolan
Chief Executive Officer
Kartik Ramamoorthi
Chief Medical Officer
Salvador Rico
Chief Operating Officer
David Oberkofler
Chief Scientific Officer
Stephanie Tagliatela
Chief Technical Officer
Martin Moorhead
VP - Bus. Development
David McNinch
VP - Human Resources
Monique Bobadilla
VP - Manufacturing
Andrew Stober
VP - Regulatory Affairs
Nancy Boman
Browse more venture capital transactions:
Prev: 6/27/2019: AUrate venture capital transaction
Next: 6/27/2019: PHLUR venture capital transaction
Share this article
News on VC Transactions
We report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs